O. A. O'Connor Et Al. , "Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma," JOURNAL OF CLINICAL ONCOLOGY , vol.37, no.8, pp.613-624, 2019
O'Connor, O. A. Et Al. 2019. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY , vol.37, no.8 , 613-624.
O'Connor, O. A., ÖZCAN, M., Jacobsen, E. D., Roncero, J. M., Trotman, J., Demeter, J., ... Masszi, T.(2019). Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY , vol.37, no.8, 613-624.
O'Connor, Owen Et Al. "Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma," JOURNAL OF CLINICAL ONCOLOGY , vol.37, no.8, 613-624, 2019
O'Connor, Owen A. Et Al. "Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma." JOURNAL OF CLINICAL ONCOLOGY , vol.37, no.8, pp.613-624, 2019
O'Connor, O. A. Et Al. (2019) . "Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma." JOURNAL OF CLINICAL ONCOLOGY , vol.37, no.8, pp.613-624.
@article{article, author={Owen A. O'Connor Et Al. }, title={Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2019, pages={613-624} }